Pomalidomide-C4-OH is a high-purity E3 Ligase Ligand-Linker Conjugate specifically designed for PROTAC (Proteolysis Targeting Chimera) drug discovery and research. As a thalidomide analog, Pomalidomide selectively binds to the cereblon (CRBN) E3 ubiquitin ligase, making it a cornerstone in the development of targeted protein degradation therapies. The C4-OH linker offers a convenient functional handle for efficient conjugation to target protein ligands, enabling the design and synthesis of versatile PROTAC molecules. Pomalidomide-C4-OH facilitates the recruitment of CRBN to degrade disease-related proteins via the ubiquitin-proteasome system. Ideal for oncology, immunology, and neurodegenerative research, this ligand-linker conjugate accelerates innovation in next-generation small-molecule therapeutics.
Structure of 2368940-93-4
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Background Introduction
Pomalidomide-C4-OH is a versatile E3 ligase ligand-linker conjugate that combines the recognized cereblon-binding moiety, pomalidomide, with a four-carbon (C4) alkyl linker terminated by a hydroxyl (OH) group. This synthetic bifunctional molecule is widely utilized in PROTAC design for targeted protein degradation. The hydroxyl group provides a reactive handle for further functionalization, allowing for the attachment of various warheads tailored to diverse research needs in chemical biology and drug development.
Mechanism
Pomalidomide-C4-OH functions by hijacking the ubiquitin-proteasome pathway through its pomalidomide moiety, which specifically binds to the E3 ubiquitin ligase cereblon (CRBN). When incorporated into a PROTAC molecule, the C4 linker serves as a flexible spacer, while the terminal hydroxyl group allows for conjugation with a ligand that selectively recognizes a protein of interest. By bringing the POI (Protein Of Interest) into proximity with the E3 ligase, the conjugate enables ubiquitination and subsequent proteasomal degradation of the target protein. This approach allows for the precise and efficient removal of disease-causing or unwanted proteins in cells.
Applications
Pomalidomide-C4-OH is widely used in the development and synthesis of PROTACs (Proteolysis Targeting Chimeras) for targeted protein degradation, a cutting-edge therapeutic and research strategy in drug discovery. Its applications include the creation of customized PROTACs for preclinical and clinical studies targeting cancers, neurodegenerative disorders, and other diseases driven by dysregulated proteins. Additionally, Pomalidomide-C4-OH serves as a foundational scaffold for the generation of chemical probes in mechanism of action studies, phenotypic screening, and target validation assays. Its ease of functionalization and compatibility with diverse warheads make it an essential tool in modern chemical biology and medicinal chemistry laboratories.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.